Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
62 hedge funds and large institutions have $233M invested in Ra Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 21 closing their positions.
80% more capital invested
Capital invested by funds: $130M → $233M (+$103M)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
18% less funds holding
Funds holding: 76 → 62 (-14)
67% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$5.36M |
| 2 |
BlackRock
New York
|
+$2.66M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.04M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$560K |
| 5 |
Goldman Sachs
New York
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.91M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$2.39M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.56M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.43M |
| 5 |
JP Morgan Chase
New York
|
-$1.2M |
RARX Hedge Fund Activity: Q2 2018 in Review
62 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q2 2018, worth a combined $233M — up 80% from $130M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of RARX and 7 opened new positions — a net loss of 14 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was First Manhattan, adding an estimated $5.36M. The largest seller was Millennium Management, cutting an estimated $2.91M.
- 62 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q2 2018, down from 76 in Q1 2018.
- Funds reported $233M of Ra Pharmaceuticals, Inc. Common Stock stock for Q2 2018, up 80% quarter-over-quarter.
- 7 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 21 closed out, a net change of -14 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was First Manhattan, an estimated $5.36M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was Millennium Management, an estimated $2.91M sold.
Based on aggregated 13F filings for Q2 2018.